Phytochemical Profiling and Biological Evaluation of Pistacia lentiscus L. grown in Chlef (Algeria): An Integrated In Vitro, In Vivo, and In Silico Study Authors: Halima Saiah, Ali Zineddine Boumehira, Wassila Saiah, Salima Boudane, Asma Al‐farajein Published: 2026 ABSTRACT ABSTRACT Pistacia lentiscus L. plays an integral role in Algerian traditional therapy. The aim of this study was to evaluate P. lentiscus methanol extract (PLME) for its potential antihypoxic and antioxidant activity and to characterize its phytochemical profile. Locomotor and exploratory behavior were investigated using the open‐field test (OF). Also, biological activity prediction was performed using the PASS online platform, and molecular docking studies were carried out using AutoDock Vina software. Quantitative investigations revealed high levels of total phenolics (713.952 ± 12.58 mg GAE/g extract) and flavonoids (315.821 ± 2.219 mg QE/g extract). The HPLC‐MS analysis identified phenolic acids and flavonoids. The extract exhibited a dose‐dependent increase in scavenging activity and reducing power. PLME could dose‐dependently enhance the survival time of mice under normobaric hypoxia and after injection of sodium nitrite. PLME significantly decreased the malondialdehyde (MDA) level compared to the control group. Furthermore, PLME increased the number of squares crossed and the number of rearings in the OF test. PLME constituents exhibited favorable binding affinities with the HIF‐1α and drug‐likeness properties. This is the first study to evaluate the antihypoxic efficacy of P. lentiscus L. extract and highlight its significance as a medicinal plant by in vivo and in silico approaches. Introduction Hypoxia is a frequent and serious problem in both clinical and extreme conditions. It causes biochemical alterations as well as morphological changes [1, 2]. The brain is particularly sensitive to hypoxia in the central nervous system. Altitude sickness causes a number of neurological symptoms, including headaches, insomnia, and even dementia, in addition to physical discomfort. These symptoms have a significant impact on cognitive functions like perception, judgment, and memory [3]. Several studies have demonstrated that chronic conditions like cardiovascular diseases, bronchial asthma, chronic bronchitis, and chronic obstructive pulmonary disease, as well as the prolonged hypoxia experienced by those who live at altitude are risk factors for anxiety disorders, depression, and suicide [4, 5]. Hypoxia leads to an imbalance between the energy produced in the mitochondrial oxidative phosphorylation system and the energy requirements of the cell [6]. It decreases the functional activity of mitochondria and increases the production of reactive oxygen species (ROS) and lipid peroxidation (LPO), which affects nerve cell function [7]. Numerous studies have demonstrated that oxidative stress is the primary cause of several forms of nervous system damage, including neuroinflammation, learning and memory problems, and certain neurodegenerative diseases [8]. Antioxidants maintain mitochondrial membrane potential, reduce LPO markers such malondialdehyde (MDA), and increase cell survival in acute oxygen deprivation by suppressing hypoxia‐induced ROS generation [9]. Several chemical drugs, including acetazolamide, dexamethasone, and nimodipine have been shown in prior research to possess notable antihypoxic effects. However, during clinical treatment, significant adverse effects have been noted, such as dizziness, paraesthesia, depression, arrhythmia, metabolic acidosis, and electrolyte abnormalities [10]. There is growing evidence that naturally occurring phytochemicals, like polyphenolic antioxidants, offer a promising strategy for mitigating hypoxic brain injury and preserving cognitive function [11]. Therefore, new alternative anti‐hypoxia therapies from natural sources are attracting the attention of an increasing number of researchers. However, scientific evidence for their mechanism of action is still lacking. Algeria boasts a significant biodiversity associated with its exceptional bioclimatic gradient and ecogeographical range, which together facilitate the growth of various species [12], including Pistacia lentiscus L. This species is widely distributed in both coastal and sub‐Saharan locations and can survive at elevations of up to 1500 meters [13]. P. lentiscus L., commonly known as Mastic tree or Lentisk is an evergreen Mediterranean shrub belonging to the Anacardiaceae family [14]. In Chlef, located in the northwestern region of Algeria, P. lentiscus is locally referred to as “El Mastic” or “Dharou”. Due to its antihypertensive, antiseptic, and gastrointestinal therapeutic properties, P. lentiscus has found extensive use in traditional medicine [15]. P. lentiscus extracts possess antioxidant [16], anti‐inflammatory [16], antibacterial [17], neuroprotective [8, 18, 19], and anticancer properties [20]. The presence of a variety of biologically active components, including phenolic compounds, has been related to lentisk's beneficial health effects. Several P. lentiscus extracts were subjected to the separation, identification, and quantification of secondary metabolites. Numerous compounds including resin [21], essential oils [22], catechins [13, 23], flavonoid glycosides, anthocyanins, and different phenolic acids (gallic acid, digallic acid, quinic acid) and their derivatives were identified [13, 19, 20, 23, 24, 25, 26]. P. lentiscus leaves are reported to contain a high concentration of polyphenolic compounds (5%–7% of the dry matter of the leaf), particularly galloyl derivatives such as mono‐, di‐, and tri‐O‐galloyl glucose and quinic acid [27]. The phytochemical components of P. lentiscus leaves cultivated in many Mediterranean countries, including Spain, Morocco, Algeria, Italy, Tunisia, Corsica, and Egypt have been extensively studied [28]. Samples from different regions of Algeria have been chemically characterized [13, 20, 26, 29, 30]. As reported by Chehrit‐Hacid et al. [31] P. lentiscus presents high intraspecific variability, with 14 compounds detected by HPLC‐DAD and more than 25 by GC‐MS, highlighting the exceptional chemodiversity of the species. Due to its Mediterranean environment, which is characterized by hot, dry summers and mild, rainy winters, the Chlef region, which is situated within the Tell Atlas Mountains offers a distinctive ecological habitat that can apply selective pressures on secondary metabolism in P. lentiscus [31]. To the best of our knowledge, the particular phenolic profile of P. lentiscus leaves from the Chlef region remains unexplored. Therefore, investigating this local sample will help us better understand the species' adaptive phytochemistry and provide a chance to find a potentially distinct chemotype that is influenced by these regional environmental factors. Additionally, earlier investigations showed that P. lentiscus oil can reduce oxidative stress and memory impairment in vivo [8] and highlighted the in vitro anti‐inflammatory and anticholinesterase properties of Pistacia species leaf extracts in the context of memory function [19]. However, the possible antihypoxic properties of P. lentiscus leaf, a condition intimately related to cerebral ischemia and cognitive decline [32, 33], and the effects of its methanolic extract on anxiety and exploratory behaviors remain unaddressed by these studies. Therefore, the present work aims to provide the first report on these properties, using a methanolic extract prepared from P. lentiscus leaves collected in Chlef (Algeria). This study is an attempt to profile the metabolites of the leaves of P. lentiscus via HPLC‐ESI‐MS analysis. Besides, the methanolic extract was assessed for its antihypoxic activity on mouse models of normobaric hypercapnic and chemical hypoxia, aiming at providing new data on the neuroprotective properties of this species. An in silico study was performed via molecular docking analysis to elucidate the binding modes between compounds identified by HPLC‐ESI‐MS and the interaction interface of the target protein. Furthermore, ADMET analyses were used to conduct a thorough pharmacokinetic profiling and toxicity assessment of the constituents related to P. lentiscus. Results and Discussion Phytochemical Results The total polyphenols content (TPC) of the extract was quantified using a gallic acid standard calibration curve (Y=0.0014X+0.1178,R2=0.961), yielding a result of 713.952 ± 12.58 mg GAE/g extract. Similarly, the total flavonoids content (TFC) was determined via a quercetin calibration curve (Y=0.003X−0.1038,R2=0.963) and found to be 315.821 ± 2.219 mg QE/g dry extract (Table 1). TABLE 1Total polyphenols and flavonoids contents in P. lentiscus leaves extract (PLME).Phytochemical assaysPLMETotal polyphenols (mg GAE/g extract)713.952 (703.714– 728.00)Total flavonoids (mg QE/g extract)315.821 (313.933–318.266)Results are expressed as Mean (Min–Max) from three measurements. GAE: Gallic acid equivalents; QE: Quercetin equivalents.John Wiley & Sons, Ltd. Total polyphenols and flavonoids contents in P. lentiscus leaves extract (PLME). Results are expressed as Mean (Min–Max) from three measurements. GAE: Gallic acid equivalents; QE: Quercetin equivalents. Numerous studies have shown the capacity of polyphenols to reduce hypoxia damage. For instance, He et al. [34] revealed that areca nut polyphenols efficiently reduce oxidative stress and apoptosis in hypoxic pulmonary microvascular endothelial cells. Similarly, Zhao et al. [35] showed that resveratrol inhibits ferroptosis, protecting against hypoxia‐related liver injury. For these reasons, we have tried to determine their amounts. Mehenni et al. [26] mentioned high amounts of total phenolics and flavonoids in P. lentiscus leaf aqueous fraction (1104.603 ± 6.7 mg CEq/g and 253.82 ± 0.46 mg REq/g, respectively), in agreement with our results and with those of previous investigators who reported that 75% of phenolic compounds of P. lentiscus are hydrolysable tannins (galloylated tannins) mostly soluble in aqueous solvents [36]. Atmani and his colleagues [37], found that the total phenols and flavonoids content of aqueous fractions of Algerian P. lentiscus leaves extracts are 452.95 ± 15.9 mg Eq Catechin/g extract and 44.25 ± 0.87 mg Eq Quercetin/g extract, respectively. According to Bouakline et al. [38], the total phenolic and flavonoid contents of P. lentiscus leaf extract determined by the Folin–Ciocalteu and aluminum chloride colorimetric methods were 394.5 ± 0.08 mg gallic acid equivalent/g dry extract (mg GAE/g DE) and 101.2 ± 0.095 mg quercetin equivalent/g dry extract (mg QE/g DE), respectively. Similarly polyphenol content was confirmed by Bampouli et al. [39], who reported that Soxhlet extraction yielded the highest total phenolic content (314.88 ± 0.01 mg GAE/g dry extract), while ultrasound‐assisted extraction of dried leaves yielded the highest total flavonoid content (106.5 ± 0.02 mg QE/g dry extract). Furthermore, when compared to prior findings on Algerian P. lentiscus from El Kala [40], which showed 306.5 mg GAE/g of total phenols and 95.25 mg RE/g of flavonoids in leaf extracts, our extract (713.952 ± 12.58 mg GAE/g extract and 315.821 ± 2.219 mg QE/g extract, respectively) appears particularly enriched in phenolic constituents. The discrepancies between our findings and the previously mentioned results may be attributed to a number of intrinsic (genetic) and extrinsic (soil composition, local microclimate, collection period, and handling and storage) factors [37, 41, 42]. The solubility of phenolic compounds is actually governed by the type of solvent employed, the degree of polymerization of phenolics, as well as by the interaction of phenolics with the other constituents and formation of insoluble complex [41]. For that purpose, methanol was recommended and frequently used for the extraction of phenolics [43, 44, 45]. Phenolic Profiling by HPLC‐PDA‐ESI‐MS Chromatographic analysis conducted at 280 nm in negative ion mode led to the identification of eight phenolic compounds in the sample, as shown in the chromatogram presented in Figure S1. The identities of the compounds, as listed in Table 2, were determined by comparing their retention times, molecular ions, and fragmentation patterns against databases and published literature. TABLE 2Quantitative and qualitative analyses of phenolics in Pistacia lentiscus leaves extract by HPLC‐PDA‐ESI‐MS.PeakRt (min)Molecular formulaIon modeMass (m/z)UV‐vis (λmax)Analyte Content (mg /g extract)Tentative identificationReference111.110C14H16O10 [M‐H]− 343276, 358NDGalloyl quinic acid[45]213.977C7H6O5 [M‐H]− 169270193.464Gallic acid[46, 47]319.174C14H16O10 [M‐H]− 343272ND5‐O‐galloyl quinic acid[47]422.431C21H20O14 [M‐H]− 495273ND3,5‐O‐digalloyl quinic acid[46]527.935C15H14O6 [M‐H]− 28927840.392Catechin[48]631.816C21H20O13 [M‐H]− 479253, 313, 358NDMyricetin‐glucoside[46]733.744C15H10O6 [M‐H]− 285260, 313, 35230.522Luteolin[46]837.781C21H20O11 [M‐H]− 447257, 311, 350NDQuercetin‐rhamnoside[49]John Wiley & Sons, Ltd. Quantitative and qualitative analyses of phenolics in Pistacia lentiscus leaves extract by HPLC‐PDA‐ESI‐MS. Considering the phytochemical screening of the studied extract by HPLC‐PDA‐ESI‐MS, eight secondary metabolites were tentatively identified in the methanol extract (Table 2 and Figure S1). Among these, four were characterized as phenolic acids and four as flavonoids. The identified phenolic acids comprised three galloyl quinic acid derivatives; galloyl quinic acid (Peak 1), 5‐O‐galloyl quinic acid (Peak 3), and 3,5‐O‐digalloyl quinic acid (Peak 4); and one hydroxybenzoic acid, gallic acid (Peak 2). Among the flavonoids, two flavonols were identified; Peak 6 was tentatively assigned as myricetin‐glucoside, and Peak 8 as quercetin‐rhamnoside. Furthermore, one flavan‐3‐ol (Catechin, Peak 5), and one flavone were detected. Based on its absorption maximum and fragmentation pattern, the flavone in Peak 7 was tentatively identified as luteolin (5,7,3',4'‐tetrahydroxyflavone). Quantification of the identified compounds, detected in the leaves‘ methanol extract, was accomplished by external standards method. The amount of each identified phenolic compound (expressed as mg/g of extract) is reported in Table 2. Particularly, gallic acid (193.464 mg/g extract) was found to be the most abundant compound, followed by catechin (40.392 mg/g extract), and finally luteolin (30.522 mg/g extract). Previous phytochemical investigations on P. lentiscus have identified a profile dominated by phenolic acids and flavonol glycosides including glucoside and rhamnoside derivatives of both myricetin and quercetin [14, 20, 27, 36, 50, 51, 52]. Our data confirmed these evidence. The results of the present work corroborate the findings of a previous study indicating that gallic acid is the most abundant compound, in P. lentiscus leaf and fruit extracts [26]. Our results are in agreement with earlier studies that successfully identified several types of phenolic acids including gallic acid [24, 52, 53], in addition, quinic acid and its galloyl derivatives were also detected [19, 24, 27, 36, 46, 51]. Some other studies also reported the presence of syringic acid, ellagic acid, 3,4‐dihydroxyhydro‐cinnamic acid, benzoic acid, salicylic acid [26], tannic acid, chlorogenic acid, caffeic acid, vanillic acid, p‐coumaric acid, p‐coumaric acid, ferulic acid, 3,4‐dihydroxybenzoic acid, 4‐hydroxybenzoic acid, and trans‐cinnamic acid [53, 54]. These compounds were not revealed in our sample either because they are absent or present at undetectable concentrations in the sample. In accordance with the present results, a previous study conducted on Algerian P. lentiscus ethanol extract reported the presence of gallic acid, catechin, quercetin 3‐O‐rhamnoside and luteolin in leaf extract of the plant. Gallic acid was the most abundant [26]. Flavanols assigned as epicatechin, catechin, epigallocatechin, epigallocatechin gallate, and epicatechin gallate were recovered in several studies [16, 27, 52, 53, 55]. Catechin was the most representative flavanol in P. lentiscus leaves extracts [38, 54]. The metabolite profiling of Algerian P. lentiscus leaves identified 46 different compounds, 20 of which were tentatively characterized for the first time in this species. Moreover, myricetin glycoside (6216.13 mg/kg of plant) was found to be the predominant flavonol glycoside, followed by catechin (3354.78 mg/kg of plant), β‐glucogallin (2214.461 mg/kg of plant), and quercitrin gallate (1160 mg/kg of plant) in the leaf methanol extract of P. lentiscus collected from Bejaia, Algeria [14]. The comparative analysis between our findings and this study reveals notable qualitative differences in the phenolic profile of P. lentiscus leaves. While we corroborated the presence of myricetin glycoside and catechin, we were unable to identify β‐glucogallin and quercitrin gallate in our methanol extract. Our phytochemical profile corroborates the distinct chemotype of P. lentiscus described by Romani et al. [27], which is characterized by the absence of kaempferol derivatives within the Anacardiaceae family. However, although the same study also previously identified anthocyanins, namely, delphinidin‐3‐O‐glucoside, cyanidin‐3‐O‐glucoside in P. lentiscus leaves ethanol extract these compounds were not detected in our chromatographic profile. The variation in the composition and levels of polyphenolic metabolites in the extracts of P. lentiscus strongly indicates significant intraspecific variability and distinct chemotypes, which is a well‐documented phenomenon for this evergreen shrub [22]. As synthesized by Floris et al. [56] the chemical fingerprint of P. lentiscus is extremely dynamic and varies significantly depending on the plant organ used, environmental stresses, and geographic origin. The response of plants to various environmental conditions is influenced by the specific roles of different types of phenolic compounds. For instance, the synthesis of flavonoids increases with higher UV radiation intensity, while tannins and simple phenolic acids, which absorb at lower wavelengths, remain unchanged. Additionally, a deficiency in soil nutrients leads to a notable rise in the levels of condensed tannins and polyphenols in the leaves [31]. Further investigation in the Tizi‐Ouzou region (Algeria) highlighted how seasonal climatic contrasts between littoral and mountain sites contribute to this variability, with colder temperatures at higher altitudes causing an overproduction of phytochemicals [29]. Researchers have identified that high morphological and chemical variability on one hand, and genotypic polymorphism on the other, might explain the distribution of P. lentiscus over a wide range of habitats [57]. Additionally, Dragović et al. [23] studied the effect of the extraction solvent on the polyphenol composition of P. lentiscus leaf extracts from four locations at three different phenological stages. They concluded that mass concentration of these compounds varied significantly according to phenological stages, cultivation sites, and extraction solvents used. P. lentiscus exhibits intraspecific chemodiversity in both volatile and non‑volatile metabolites. Furthermore, a key role is played by the extract preparation technique, which includes the extraction methodology, time, solvents employed, and solvent to solid material ratio [12]. In Algeria, a study reported that female plants of P. lentiscus L. growing along a climatic contrast between coastal lowlands and mountains exhibit distinct terpene profiles. PCA‐based analyses resolved three distinct chemotypes associated with the combined effects of genetic factors, temperature, and drought along the altitudinal level [30]. Secondary metabolites' chemical diversity offers a broad spectrum of pharmacological activities that are significantly extended by their combinations in plant extracts [6]. Although three key marker molecules (gallic acid, catechin, and luteolin) were identified and quantified with the use of external standards, the additional five phytoconstituents detected in the HPLC chromatogram, galloyl quinic acid, 5‐O‐galloyl quinic acid, 3,5‐O‐digalloyl quinic acid, myricetin‐glucoside, and quercetin‐rhamnoside, were identified only tentatively, based on spectral data matching with literature and molecular ion fragmentation patterns. Since these additional peaks lack commercial standards, their precise isomeric forms and absolute stereochemistry are still fully unknown. In Vitro Antioxidant Activity The antioxidant capacity of P. lentiscus methanol extract (PLME) has been evaluated using two approaches. DPPH Radical Scavenging Activity The DPPH· test was used to examine the extract's (PLME) potential capacity to neutralize free radicals. Figure 1a displays the results of this evaluation. The figure clearly illustrates the extract's dose‐dependent antioxidant action. In particular, the percentage of DPPH scavenging activity increases significantly (p < 0.05) from 17.42 ± 0.11% to 95.53 ± 3.32% when the concentration of PLME increases from 0.0625 mg/mL to 1 mg/mL, suggesting that higher extract doses result in greater free radical neutralization. The extract showed a 75.69 ± 1.43% antioxidant activity at 0.75 mg/mL, which was significantly (p < 0.05) lower than that of ascorbic acid (94.92 ± 3.00 %). PLME and the well‐known antioxidant ascorbic acid did not vary significantly (p > 0.05) in their ability to scavenge DPPH radicals at higher concentrations (1 mg/mL to 10 mg/mL). Dose‐dependent antioxidant activity of PLME measured by DPPH (a) and FRAP (b) assays. Data is shown as mean with error bars marking the range (n = 3). Means at the same concentration with different symbols are significantly different at p < 0.05. FRAP Assay The ability of the compounds to reduce Fe3+ to Fe2+ is frequently assessed using the reducing power test. The findings showed that the extract may undergo an electron transfer process and convert Fe3+ to Fe2+. The extract's reducing power is plotted against concentration in Figure 1b. P. lentiscus extract's reducing capacity was found to be concentration dependent. All tested concentrations showed a significantly greater absorbance (p < 0.05) for the standard antioxidant ascorbic acid than for the extract. A plateau in absorbance readings is observed at greater concentrations. The extract displayed absorbances of 1.042 ± 0.010 and 1.044 ± 0.004 at concentrations of 7 and 10 mg/mL, while ascorbic acid displayed absorbances of 1.158 ± 0.074 and 1.156 ± 0.080, respectively. Several phenolic substances with antioxidant properties are present in the studied extract, including gallic acid, galloyl quinic acid derivatives, and flavonoids such as luteolin, myricetin‐glucoside, catechin, and quercetin derivatives. Gallic acid is widely used in the pharmaceutical industry due to its exceptional antioxidant abilities, which have been shown in a number of in vitro and in vivo investigations [58]. Baratto et al. [47] reported that the free radical scavenging activity of galloyl quinic derivatives from P. lentiscus leaves is enhanced with a higher number of galloyl groups attached to the quinic acid core. The authors revealed that the structure‐activity relationship was evident in the potent inhibition demonstrated by di‐ and tri‐galloyl derivatives, which exhibited IC50 values below 30 µM against all tested radicals. Flavonoids exhibit antioxidant properties due to distinct structural characteristics. The critical features are a catechol‐like B‐ring and a 2,3‐unsaturated C‐ring conjugated with a 4‐carbonyl group. This configuration allows flavonoids to scavenge ROS‐including hydroxyl, peroxyl, and peroxynitrite radicals…by acting as donors of both hydrogen atoms and electrons [59]. Recent studies, utilizing both experimental and computational approaches have demonstrated the potent free radical scavenging and metal chelation capabilities of catechin and its derivatives across various in vitro and in vivo models [60]. According to Sheng et al. [61], catechin exerts its antioxidant effects through a dual mechanism: it inhibits enzymes responsible for ROS production and activates endogenous antioxidant systems via the Keap1/Nrf2/ARE signaling pathway. Moreover, myricetin is often regarded as the most potent antioxidant among flavonoids because its six hydroxyl groups significantly enhance its free radical scavenging capacity and redox properties [62]. A study published by Fernanda Arias‐Santé et al. [63] demonstrated that the autooxidation of myricetin significantly amplifies its antioxidant activity, suggesting that metabolic or oxidative modification enhances its properties. Numerous studies and comprehensive reviews highlight luteolin's role in enhancing cellular antioxidant defenses by upregulating key enzymes like SOD, CAT, and glutathione peroxidase [64]. The oxidation product of quercetin, 2,5,7,3',4'‐pentahydroxy‐3,4‐flavan‐dione, maintains its potent DPPH‐radical scavenging ability, as demonstrated by Atala et al. [65]. Pharmacological Studies Acute Toxicity Assay The acute toxicity study revealed no mortality or visible signs of toxicity in mice at a limit dose of 2000 mg/kg, within the first 24 h and over the 14‐day observation period. Consequently, the median lethal dose (LD50) of the crude extract was determined to be greater than 2000 mg/kg body weight. Normobaric Hypercapnic Hypoxia Assay The protective effects of P. lentiscus methanol extract (PLME) and the standard drug piracetam on mouse life span under hypoxia were determined. Piracetam significantly prolonged survival time under normobaric hypercapnic hypoxia by 65.4% compared to the control (p < 0.001), indicating a potent therapeutic effect against hypoxic injury. The treatment with PLME at 200 mg/Kg and 400 mg/Kg resulted in the life span of mice under hypoxia being increased 17.3% (p < 0.05), and 33.3 % (p < 0.001), respectively with respect to the control (Table 3). TABLE 3Effect of PLME on the life span and MDA level under hemic and normobaric hypercapnic hypoxia in mice.TreatmentLife span, minPercentage of prolonged time (%)MDA level (nmol/mg) a Hemic hypoxia (sodium nitrite) Blank control21.66 ± 1.63—15.56 ± 1.42Piracetam (400 mg/Kg)38.83 ± 5.03 *** 79.305.52 ± 0.65 *** PLME (200 mg/Kg)27.16 ± 2.31 * 25.409.87 ± 0.61 *** PLME (400 mg/Kg)35.33 ± 3.26 *** 63.107.76 ± 0.48 *** Normobaric hypercapnic hypoxia Blank control26.00 ± 1.78—Piracetam (400 mg/Kg)43.00 ± 5.40 *** 65.4PLME (200 mg/Kg)30.50 ± 3.14 * 17.3PLME (400 mg/Kg)34.66 ± 1.21 *** 33.3 a MDA is malondialdehyde. The presented values correspond to Mean ± SD (n = 6); ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 (Dunnett's test) values are statistically significant compared with the blank control group.John Wiley & Sons, Ltd. Effect of PLME on the life span and MDA level under hemic and normobaric hypercapnic hypoxia in mice. MDA is malondialdehyde. The presented values correspond to Mean ± SD (n = 6); ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 (Dunnett's test) values are statistically significant compared with the blank control group. Sodium Nitrite Toxicosis Test As shown in Table 3, piracetam significantly extended the life span under hemic hypoxia by approximately 79% (p < 0.001), indicating a potent protective effect against hypoxic damage. Administration of the extract (PLME) at two doses (200 mg/kg and 400 mg/kg) significantly prolonged the survival time of mice with sodium nitrite (NaNO2) toxicosis compared to the control group. The effect was dose‐dependent, with the lower dose producing a moderate 25.4% increase (p < 0.05) and the higher dose yielding a substantial 63.1% increase (p < 0.001). Biochemical Analysis‐MDA Table 3 presents the effects of the extract (PLME) and piracetam on MDA levels‐a key biomarker of oxidative stress and LPO‐in mice subjected to hemic hypoxia. Both piracetam and PLME confer significant antioxidant protection against oxidative damage induced by hemic hypoxia, as evidenced by reduced MDA levels. Piracetam at 400 mg/kg significantly reduced MDA levels to 5.52±0.65 nmol/mg (p < 0.001), showing a strong protective antioxidant effect by decreasing LPO during hypoxia. PLME demonstrated a dose‐dependent antioxidant effect by reducing MDA levels to 9.87±0.61 nmol/mg at 200 mg/kg and further to 7.76±0.48 nmol/mg at 400 mg/kg (both p < 0.001). However, its antioxidant efficacy was less pronounced than that of piracetam at the tested doses. Open‐Field Test The open field test was designed to evaluate the effect of P. lentiscus extract (PLME) on the number of squares crossed (Figure 2a), the number of rearings (Figure 2b), and grooming episodes (Figure 2c) relative to the blank control group. Results of the open field test upon administration of PLME at 200 and 400 mg/kg doses (Mean ±SD, n = 6). Number of crossed squares (a); number of rearing episodes (b); number of grooming acts (c). *p < 0.05, **p < 0.01, ***p < 0.001 (Dunnett's test) values are statistically significant compared to the blank control group. Compared with the blank control (29 ± 6.95), piracetam treated group showed a significantly (69.5 ± 7.47; p < 0.001) higher number of square crossings. PLME at 200 and 400 mg/Kg significantly (p < 0.001) increased locomotor activity compared to the blank control as indicated with a strong increase in square crossings (44.66 ± 4.88 and 57.5 ± 6.09, respectively). With respect to number of rearings, at the lower dose (200 mg/Kg), no significant difference was detected between PLME (10.33 ± 1.63) and the control group (09.16 ± 2.99). The higher dose of PLME and the standard drug treated groups showed significantly high number of rearings (15.83 ± 3.37, p < 0.001 and 19 ± 02, p < 0.001, respectively) (Figure 2b). In relation to grooming, results showed that the administration of the extract at a 400 mg/Kg dose resulted in a significant increase in the number of grooming acts (11.16 ± 5.82, p < 0.01) when compared to the control group (5.66 ± 1.36) (Figure 2c). Nevertheless, PLME (200 mg/kg) and piracetam did not show significant differences in comparison to control. The purpose of this study was to assess the effect of P. lentiscus extract on mice survival time under conditions of normobaric hypoxia with hypercapnia and sodium nitrite‐induced hemic hypoxia, as well as to assess the antioxidant properties of the extract on the background of toxic hypoxia. Its impact on the behavior in the open field test in intact (without pathology) rats was also evaluated. Since the final product of free radical peroxidation with lipids is MDA, MDA content is usually used to assess the degree of tissue membrane system damage. The substantial increase in brain LPO induced by hypoxia, along with corresponding higher MDA levels (p < 0.001) in comparison to PLME‐treated animals, justifies increased production of free radicals in the brain and supports the extract's enhancement of the antioxidant defense system against oxidative stress caused by sodium nitrite. This supports a previous report on the crucial role of inhibiting free‐radical‐mediated MDA formation in preventing sodium nitrite‐induced hypoxia, which is corroborated by the authors' determination of cerebral MDA levels and their evidence demonstrating that treatment with the Chelesta‐8,24‐dien‐3‐ol from Ficus exasperata leaves significantly lowered these elevated concentrations [66]. Researchers have documented that excessive intracellular nitrite can induce oxidative/nitrosamine stress, by inactivating membrane‐bound enzymes and inducing exhaustion of the antioxidant capacity ultimately increasing the porosity of the membrane resulting from LPO [67, 68]. Moreover, Lüneburg et al. [69] demonstrated a clear increase in oxidative stress under both chronic intermittent hypoxia (CIH) and chronic hypoxia (CH) conditions. MDA increased up to 2‐fold equally in both hypoxic groups compared to normoxic controls (p < 0.001). Additionally, NOX4 expression, a key enzyme in ROS production, increased specifically under CH (p < 0.01). These findings provide direct evidence that chronic hypoxic exposure, whether intermittent or continuous, triggers a significant oxidative stress response. Mitochondria are abundant in cerebral tissue, and mitochondrial complex I is a major source of cerebral intracellular ROS [70]. Hypoxia/reoxygenation (H/R) triggers the mitochondrial apoptotic cascade by stimulating substantial ROS generation and the impairment of mitochondrial membrane potential, which prompts cytochrome C release and caspase‐9 and caspase‐3 activation, subsequently resulting in apoptosis [71]. Corroborating our observations, Ma et al. [33] reported that oral administration of a formulation of Edaravone, a free radical scavenger, approved for the treatment of ischemic stroke and amyotrophic lateral sclerosis, significantly alleviated oxidative stress and cognitive impairments caused by chronic hypobaric hypoxia. Additionally, evidence from a prior study suggests that the polyphenolic profile of P. lentiscus extract can modulate cellular antioxidant defense systems. It achieves this by activating key enzymes such as superoxide dismutase (SOD), catalase, and glutathione peroxidase. Furthermore, the authors suggested that increasing the extract dose may lead to a more robust stimulation of these pathways, resulting in enhanced ROS detoxification and greater mitigation of oxidative stress [51]. Based on this observation, we hypothesized that the extract's metabolites might protect cell membranes, prevent LDH leakage, and ultimately prolong the mice's life by scavenging free radicals produced during hypoxia [10]. Our findings align with previous research, notably Ammari et al. [8] who showed that oral administration of P. lentiscus oil (PLo) significantly mitigated lipopolysaccharide (LPS)‐induced memory impairment and oxidative stress in rats. Specifically, PLo reduced cholinesterase activity and LPO in brain tissue, highlighting its antioxidant and neuroprotective actions. The chemometric discrimination performed by El Bishbishy et al. [19] revealed that P. lentiscus leaves are particularly rich in gallic acid derivatives and flavonols glycosides compared to other Pistacia species. Interestingly, the authors noted a strong correlation between these specific metabolites and anti‐memory decline activity. Galloyl quinic acid derivatives isolated from P. lentiscus leaves are highly effective in lowering LPO, a critical indicator of oxidative stress damage often highlighted during hypoxia [47]. Similarly, a study on 3,5‐O‐di‐galloylquinic acid (DGQA) from Myrtus communis revealed potent antioxidant activity. The pure molecule inhibited H2O2‐induced LPO in K562 cells by 82.2%, as measured by MDA formation [72]. Previous research in this field has consistently shown that gallic acid inhibits ROS and inflammatory cytokines production in microglia. Furthermore, the compound improves motor and cognitive outcomes by lowering neuroinflammation and neuronal loss in rats with hypoxic‐ischemic brain damage (HIBD) [73]. Gallic acid was demonstrated to be neuroprotective in 2014 by Sun et al. [70]. Their research, using both in vitro hypoxia/reoxygenation models and in vivo middle cerebral artery occlusion (MCAO) rat models, showed that the compound enhanced cell viability and mitochondrial function by scavenging ROS and inhibiting the mitochondrial permeability transition pore. Liu et al. [74] further confirmed these protective effects in vivo, demonstrating that gallic acid treatment provides neuroprotective benefits against spinal cord ischemia/reperfusion injury in rats by inhibiting the production of proinflammatory factors. In vitro, gallic acid decreased the production of ROS and MDA, while also preventing neuronal apoptosis through the enhancement of the Nrf2/HO‐1 signaling pathway. Flavonoids, with a catechol group, have been recognized as SOD mimics and scavengers and play an essential role in oxidative stress [75]. A prior investigation on myricitrin, a glycoside derivative that is closely related to myricetin‐glucoside, found that myricitrin pretreatment during H/R significantly elevated the activities of SOD, GSH‐Px, and CAT and decreased levels of MDA, suggesting that the cardioprotective effects of myricitrin against I/R are largely associated with its antioxidative capacity. Further, the authors speculated that Hsp90 is one of the targets of myricitrin to relieve the H/R injury of cardiomyocytes [71]. Additionally, Zou et al. [76] in their study revealed that myricetin supplementation preserved mitochondrial structure, mtDNA content, membrane potential, and respiratory chain complexes activities in skeletal muscle. The same study showed that myricetin maintained mitochondrial biogenesis in skeletal muscle cells under hypoxic conditions by up‐regulating the expression of mitochondrial biogenesis‐related regulators. Key energy regulator, AMP‐activated protein kinase (AMPK), activity was associated with this impact. Notably, Cong et al. [77] reported that catechin significantly improved cardiac function and simultaneously reduced lncRNA MIAT expression in myocardial tissue following I/R injury in rats. Furthermore, the in vitro work confirmed that catechin protects H9C2 cells from H/R‐induced apoptosis. Lv et al. [78] reviewed the therapeutic effects of luteolin in pulmonary conditions like acute respiratory distress syndrome (ARDS) and acute lung injury (ALI), emphasizing its anti‐inflammatory, antioxidant, and mitochondria‐protective properties that lower inflammation and oxidative stress in hypoxic lung tissues. They elucidated that luteolin's protective effects are orchestrated through multiple interconnected pathways, including the regulation of HIF‐1α/HIF‐2α, activation of the PI3K/AKT/eNOS‐NO signaling axis, and upregulation of the oxygen‐sensitive potassium channel Kv1.5. While the MDA data successfully bridges the gap between our in vitro antioxidant assays and the in vivo physiological response, PLME constituents seem to us promising compounds that require further research on their effects on the expression or activity of endogenous antioxidant enzymes and key transcriptional factors such as HIF‐1α or Nrf2/ARE. Moreover, additional investigations focusing on their effects on cognitive functions on models of pathologies associated with memory damage caused by hypoxia are crucial. I n Silico Evaluation of Biological Activity In order to identify potential targets and pharmacological effects related to the eight P. lentiscus compounds, we used the online platform PASS. The number of effects displayed by the PASS, for each compound, is provided in Table S1. We selected the predicted properties with values of P a ≥ 0.3. The reference compound, piracetam showed to have antihypoxic potential (Pa= 0.756), validating the predicted results. Peroxidase inhibition activity was predicted with the highest probability for most phytocomponents. It varied from 0.608 (Galloyl quinic acid) to 0.982 (Myricetin‐glucoside). Free radical scavenger activity was predicted for all compounds. P a value for this activity varied from 0.570 (Gallic acid) to 0.982 (Myricetin‐glucoside). Myricetin‐glucoside, galloyl quinic acid, quercetin‐rhamnoside, and luteolin are strongly predicted as HIF‐1α expression inhibitors with Pa values of 0.89, 0.833, 0.921, and 0.964, respectively. Antioxidant activity was strongly predicted for all compounds, with P a values between 0.513 (Galloyl quinic acid) and 0.936 (Myricetin‐glucoside). Six compounds show moderate potential for antihypoxic effect, ranging from 0.370 (Quercetin‐rhamnoside) to 0.724 (Quercetin 3‐O‐rhamnoside). The result of the prediction mentioned in Table S1 shows that most of the main phytocomponents may reveal free radical scavenger, antioxidant, HIF‐1α expression inhibitory, and antihypoxic effects leading to additive or synergistic action. It is a reason to study the antihypoxic effect of P. lentiscus extract in the experiment. Molecular Modelling Results The molecular docking simulations of the extract's constituents (gallic acid, catechin, and luteolin) and the standard molecule, 7‐hydroxylamellarin A, with the human hypoxia‐inducible factor 1‐alpha (HIF‐1α) (PDB ID: 1H2K) offer a thorough comparison of their molecular processes, affinities, and binding interactions. Each ligand‐protein complex's binding energy and interaction profile is compiled in Table 4. On the other hand, Figure 3 displays the relevant molecular interaction diagrams for each complex with additional 3D and 2D binding designations. TABLE 4Summary of the interactions of 7‐hydroxylamellarin A, gallic acid, catechin, and luteolin with the amino acids residues within hypoxia‐inducible factor 1 alpha (HIF‐1α).Ligand–Protein ComplexBinding energy (kcal.mol−1)Interaction typeResidueDistance (Å)Angles/Parameters (°)7‐hydroxylamellarin A–HIF‐1α (1H2K)−9.4Hydrogen BondGLN1472.526160.068π‐Cation (Electrostatic)ARG2384.17129.217π‐π Stacked (Hydrophobic)TYR1024.00031.002, 19.147,HIS1994.70412.143, 3.55728.453, 58.794, 32.673, 3.542Gallic acid–HIF‐1α (1H2K)−6.3Hydrogen BondASN2052.775107.259ASN2052.040144.765ASN2941.975175.064ASP2012.549111.782GLN1472.418112.524π‐π T‐shaped (Hydrophobic)HIS1995.55568.984, 19.153, 62.989, 4.337π‐Alkyl (Hydrophobic)LEU1884.641—Catechin–HIF‐1α (1H2K)−8.1Hydrogen BondGLN1472.020133.591TYR1022.261144.445π‐π Stacked (Hydrophobic)TYR1023.92318.406, 19.845, 13.577, 3.5π‐π T‐shaped (Hydrophobic)HIS1995.08879.264, 22.942, 67.785, 3.777TRP2965.25259.917, 19.024, 77.941, 3.688π‐Alkyl (Hydrophobic)HIS1994.869—LEU1885.348—ILE2815.368—Luteolin–HIF‐1α (1H2K)−8.0Hydrogen BondTYR1022.598102.096HIS2792.941105.019π‐π Stacked (Hydrophobic)TYR1024.24030.48, 27.03, 24.084, 3.421π‐π T‐shaped (Hydrophobic)HIS1995.31154.797, 19.082, 73.635, 4.067HIS1995.14580.557, 13.051, 74.038, 4.046TRP2965.15867.37, 18.289, 78.407, 3.568π‐Alkyl (Hydrophobic)LEU1885.419—LEU1885.344—ILE2815.311—John Wiley & Sons, Ltd. Summary of the interactions of 7‐hydroxylamellarin A, gallic acid, catechin, and luteolin with the amino acids residues within hypoxia‐inducible factor 1 alpha (HIF‐1α). 3D and 2D intermolecular interactions of 7‐hydroxylamellarin A (a), Gallic acid (b), Catechin (c), and Luteolin (d) with the amino acid residues within the binding pocket of HIF‐1α (PDB ID: 1H2K) using discovery studio 2025. The docking analysis showed that the standard molecule, 7‐hydroxylamellarin A, achieved the most favorable score (−9.4 kcal.mol−1) compared to the tested ligands that exhibited binding free energies in the range from −6.3 to −8.1 kcal·mol− 1. The higher binding energy (−9.4 kcal.mol−1) of the standard drug, 7‐hydroxylamellarin A, suggests a stronger predicted binding affinity. It engages in key hydrogen bonding between its hydroxyl hydrogen (H17) and the amide carbonyl oxygen of GLN147:O at 2.526 Å (angle: 160.068°), which contributes to a strong polar stabilization of the complex (Figure 3a). Interestingly, the high binding affinity of −9.4 kcal.mol−1 is mainly driven by a strong Pi‐cation interaction measured at 4.171 Å, where the positively charged guanidinium group of ARG238:NH2 electrostatically interacts with the aromatic π‐electrons of the ligand. This electrostatic contact is enhanced by two parallel Pi‐Pi stacked interactions with the aromatic side chains of TYR102 (4.00 Å) and HIS199 (4.704 Å), which reinforce the ligand's hydrophobic core within the binding pocket. The molecular docking analysis showed that gallic acid binds to the target protein with a binding energy of −6.3 kcal.mol−1. For instance, gallic acid forms three conventional hydrogen bonds with the side‐chain amide hydrogens of ASN205 (HD21‐O4 and HD22‐O5) and ASN294 (HD21–O5) (Figure 3b). Two additional conventional hydrogen bonds are noticed between gallic acid's hydroxyl hydrogens (H6, H3) and the protein acceptors ASP201:OD2 and GLN147:OE1, respectively. The corresponding donor‐acceptor bond lengths are 2.775, 2.04, 1.975, 2.549, and 2.418 Å, with bond angles of 107.259°, 144.765°, 175.064°, 111.782°, and 112.524°, respectively. Additionally, gallic acid forms hydrophobic bonds that anchor its aromatic core within the protein's non‐polar pocket. The first is a Pi–Pi T‐shaped stacking interaction between the ligand's aromatic ring and the imidazole side chain of HIS199, characterized by a centroid‐to‐centroid distance of 5.555 Å and geometric parameters (68.984°, 19.153°, 62.989°, and 4.337°), that validates a perpendicular, edge‐to‐face characteristic of a T‐shaped orientation. Furthermore, a Pi‐Alkyl hydrophobic interaction was established between the π‐electron system of gallic acid and the aliphatic side chain of LEU188, measured at 4.641 Å. Molecular docking of catechin against the target protein exhibited a binding free energy of −8.1 kcal.mol−1. Catechin forms strong directional polar interactions, bonded by a very short hydrogen bond between the amide hydrogen of GLN147:HE21 and the hydroxyl oxygen O2 (2.02 Å, 133.591°), reinforced by another strong, nearly linear bond between H14 and the phenolic oxygen of TYR102:OH (2.261 Å, 144.445°) (Figure 3c). It also engages in aromatic bonds, comprising a parallel Pi–Pi stacked interaction with TYR102 at 3.923 Å. Two supplementary Pi–Pi T‐shaped contacts are established with HIS199 (5.088 Å) and TRP296 (5.252 Å), where the planar aromatic rings are perpendicular to each other. Moreover, three Pi‐Alkyl interactions with the alkyl side chains of ILE281 (5.368 Å), LEU188 (5.348 Å), and HIS199 (4.869 Å) confer a hydrophobic stabilization. A computed binding free energy of −8.0 kcal.mol−1 was found when luteolin was docked against the target protein. Two moderate conventional hydrogen bonds are revealed by geometric analysis of the interactions (Figure 3d). The first is established between luteolin's hydroxyl hydrogen H10 and the phenolic oxygen of TYR102:OH, with a donor–acceptor distance of 2.598 Å and a bond angle of 102.098°. In the second, the ligand's hydrogen H8 donates to the imidazole nitrogen of HIS279 at an angle of 105.019° and a distance of 2.941 Å. Both are considered as conventional hydrogen bonds, but their elongated and strongly bent angles, comparatively to the ultra‐short bonds found in gallic acid and catechin, suggest that they are moderate‐to‐weak stabilizing interactions. Particularly, an extensive network of hydrophobic contacts is the main origin of the high binding affinity. A parallel Pi–Pi stacked contact is formed with the aromatic ring of TYR102 at a centroid distance of 4.240 Å (parameters: 30.48, 27.03, 24.084, and 3.421°), improving the hydrogen bond with the same residue. Luteolin is also involved in three Pi–Pi T‐shaped interactions: two with different faces of HIS199 at 5.311 Å (parameters: 54.797°, 19.082°, 73.635°, and 4.076°) and 5.145 Å (parameters: 80.557°, 13.05°,1 74.038°, and 4.046°), and one with TRP296 at 5.158 Å (parameters: 67.37°, 18.289°, 78.407°, 3.568°). Near‐perpendicular aromatic arrangements, a feature of stable edge‐to‐face geometries, are confirmed by large angular parameters. Three Pi‐Alkyl interactions, two with the side chain of LEU188 (5.419 Å and 5.344 Å) and one with ILE281 (5.311 Å), complete the hydrophobic network and further stabilize the ligand's aliphatic regions. Molecular docking analyses indicate that the stabilization of ligands (gallic acid, catechin, and luteolin) within the HIF‐1α binding pocket is a function of their binding interactions, which vary with ligand structure. The greatest binding affinities are frequently observed for ligands that engage in the site through both hydrogen bonding and multiple π‐interactions [79]. In the present study, the molecular docking simulation of gallic acid against the HIF‐1α yielded a negative binding free energy of 6.3. In the Autodock Vina context, values lower than −5 signify the result is meaningful. Higher absolute values of binding energy display stronger affinity [80]. Furthermore, this result aligns closely with the docking parameters of established reference controls targeting HIF‐1α. For instance, the well‐characterized inhibitor 2‐Methoxyestradiol (2‐ME2) has been reported to exhibit a comparable binding affinity of −6.68 kcal.mol−1 [81]. He et al. [82] demonstrated that compounds with docking affinities ranging from −9.035 to −5.838 kcal.mol−1 against HIF‐1α form significant interactions with the target protein. Our three evaluated ligands all fall within this validated range, confirming that they establish favorable and energetically significant interactions with HIF‐1α. Gallic acid exhibited a LE (Ligand efficiency) of 0.53 kcal.mol−1.atom−1. This value approaches the 0.5 standard for highly effective binders [83]. This efficiency, combined with its broad hydrogen‐bonding network, positions gallic acid as a promising candidate. According to standard criteria [82] strong hydrogen interactions display donor‐acceptor lengths lower than 2.5 Å. Hydrogen bond strength rises when the bond angle approaches 180°, as this linear configuration improves orbital overlap and electrostatic contact between the donor and acceptor. With a nearly ideal, extremely linear angle of 175.064° and an exceptionally short distance of 1.975 Å, the interaction between ASN294:HD21 and gallic acid:O5 exhibits characteristics of strong hydrogen bonds, suggesting a potent compound‐protein interaction; in comparison with the reference ligand. Furthermore, the hydrogen bonds formed between catechin and the target protein can be defined as strong directional interactions based on their geometric parameters. The consistency between our results and prior structural analyses is notable. The binding conformation of phenolic ligands within the HIF‐1α pocket has been described in earlier research, which revealed that van der Waals interactions, Pi‐Alkyl, and Pi–Pi T‐shaped stacking are the main stabilising forces [66]. Further, genistein (a flavonoid) possessing a rigid cyclic framework and hydrophobic substituents binds to the FIH‐1 binding site of HIF‐1α protein [84]. Our current data, directly corroborate the biological relevance of these structural observations. In this study it was observed that pretreatment with different doses of PLME were able to prolong the survival time of mice with sodium nitrite (NaNO2) toxicosis and normobaric hypoxia with hypercapnia compared to the control group (p < 0.001). This implies that PLME beneficial phytochemicals revealed by HPLC‐MS analysis might have synergistically modulated the excessive expressions the HIF‐1α protein induced by sodium nitrite intoxication. These observations corroborate with previous studies that phenolic compounds are responsible for tissue protection through their significant and direct inhibitory action toward HIF‐1α during sodium nitrite‐induced hypoxic stress [66]. For instance, a previous study demonstrated that high‐altitude hypoxia exacerbates nonalcoholic fatty liver disease (NAFLD) via HIF‐1α‐dependent ferroptosis. Crucially, that study established that Resveratrol exerts its therapeutic effects precisely by targeting this HIF‐1α‐mediated pathway [35]. These discoveries agree with the work of Mylonis et al. [85], who examined the effect of kaempferol (a flavonoid) on HIF‐1 activity and the survival of Huh7 hepatocarcinoma cells cultured under hypoxia. Their findings indicate that kaempferol treatment reduced HIF‐1 activity dose‐dependently and caused HIF‐1α to mislocalize to the cytoplasm via inactivation of p44/42 MAPK. In their analysis Gamal‐Eldeen et al. [86] examined the antihypoxic effect of a polysaccharide extract of the brown seaweed Sargassum dentifolium in tongue squamous cell carcinoma. Algal polysaccharides demonstrated a possible anti‐hypoxic effect by improving HIF‐1α regulators. Hypoxia‐inducible transcription factor‐1 (HIF‐1), a heterodimeric transcription factor composed of an alpha and a beta subunit [2]. Transitory HIF‐1α increase commonly plays a cytoprotective role in physiological hypoxia [65]. Under normoxic conditions, HIF‐1α is hydroxylated by Fe2+ dependent HIF prolyl hydroxylases (PHDs) at two proline residues (402 and 564) located in the oxygen dependent degradation domain. This modification labels the HIF‐1α for fast proteasomal degradation [87]. Conversely, under systemic tissue hypoxia conditions, mitochondria generate ROS that oxidize Fe2+ to Fe3+, inhibiting PHDs’ activity and accelerating HIF‐1α stabilization and accumulation [88]. Once accumulated, HIF‐1α binds to HIF‐1β and forms heterodimers, which translocate to the nucleus to orchestrate the transcriptional activation of target genes [89]. This process induces pathogenic cascade by increasing glycolytic metabolism, promoting angiogenic dysregulation, and synergistically amplifying the NF‐κB‐driven inflammatory pathway [66]. According to our in vitro and in vivo antioxidant data, P. lentiscus extract effectively operates to directly scavenge these ROS. Therefore, we hypothesize that the extract's reduction of intracellular ROS inhibits the oxidative conversion of Fe2+ cofactors to Fe3+ hence maintaining the activity of prolyl hydroxylase (PHDs) and allowing constitutive degradation of HIF‐1α even in hypoxic conditions. Additionally, our theoretical docking models may support the premise that phytochemicals from P. lentiscus intervene precisely at this juncture by directly binding to HIF‐1α, thereby; preventing its translocation to the nucleus. This sequestration can prolong mice survival time by attenuating the HIF‐1α‐dependent upregulation of the pro‐death factors BNIP3 and NIX and restoring cellular homeostasis [90]. However, it is important to note that these results are still computational predictions based on in silico modeling. Therefore, in order to verify the suggested molecular interactions and their direct contribution to the reported biological effects, direct experimental validation is required. In Silico ADMET Analysis Swiss ADME and pKCSM webservers were employed to conduct a comprehensive ADMET (absorption, distribution, metabolism, excretion, and toxicity) screening of P. lentiscus components, predicting important toxicity parameters, such as hepatotoxicity, the AMES assay (Salmonella typhimurium reverse mutation test), and the lethal dose (LD50) of each compound. Table S2 presents an in silico drug‐likeness profile comparison of three P. lentiscus phenolic compounds; gallic acid, catechin, and luteolin and the standard drug; piracetam. These compounds vary widely in molecular weight, from 170.12 Da (gallic acid) to 286.24 Da (luteolin), affecting their drug‐likeness and absorption characteristics. All tested compounds (gallic acid, catechin, and luteolin), and the reference drug piracetam, complied with Lipinski's, Veber's, and Egan's rules, indicating favorable oral drug‐likeness. Absorption profiles revealed moderate‐to‐high human intestinal absorption (43.374%–81.13%) for all compounds, with piracetam exhibiting the highest predicted permeability (85.483%). However, catechin and luteolin were found to be P‑glycoprotein substrates, and luteolin demonstrated potential CYP1A2 and CYP2C9 inhibition, suggesting possible drug‐drug interactions. Distribution analysis showed negative blood‐brain barrier (BBB) permeability levels, with piracetam having the lowest negative log BB (−0.31), indicating comparatively improved CNS accessibility. Interestingly, toxicity profiling showed that piracetam was unexpectedly predicted to be AMES‐positive and hepatotoxic in silico, while gallic acid, catechin, and luteolin were suggested to be non‐mutagenic (AMES‐negative) and non‐hepatotoxic. Although luteolin showed a little better tolerance (higher LD50), the acute oral toxicity (LD50) values were limited to a narrow range of 2.218–2.455 mol/kg, indicating comparable safety profiles. With gallic acid exhibiting the highest tolerance (3.06 log mg/kg bw/day) and luteolin the lowest (2.409 log mg/kg bw/day), chronic toxicity (LOAEL) values vary more widely, suggesting variations in long‐term safety profiles. Importantly, none of the molecules show signs of skin sensitization or hepatotoxicity, indicating that they are mostly safe for liver function and unlikely to result in allergic skin reactions. The pharmacokinetic profile of piracetam supports its usage as an oral CNS drug. Nonetheless, it indicates possible safety issues with favorable predictions for hepatotoxicity and AMES toxicity. Collectively, PLME compounds show better preliminary safety profiles than the reference drug; however, their moderate BBB penetration requires further investigation for CNS‐targeted applications. Conclusions Chromatographic analysis of P. lentiscus methanol extract (PLME) identified eight phenolic compounds, including four phenolic acids and four flavonoids. Pharmacological assays of PLME in vivo demonstrated that it did not display any apparent toxic effect on the acute oral toxicity test at a dose of 2000 mg/kg. Furthermore, the in vivo assays revealed that the extract showed a pronounced antihypoxic activity comparable with that of piracetam used as a reference agent. Additionally, the extract significantly increased square crossings and rearings, indicating enhanced locomotor and exploratory activity. Nevertheless, the concomitant rise in grooming behavior suggests a possible stress‐ or excitation‐related component that requires further elucidation. The second major finding was that PLME revealed strong in vitro free radical scavenging and ferric reducing potential, and in vivo LPO inhibition activity. According to the molecular docking data, antihypoxic activity may be associated with the favorable binding interactions of the extract's metabolites with HIF‐1α. ADMET predictions revealed favorable drug‐likeness, absorption, and safety for P. lentiscus compounds compared to piracetam. However, their modest BBB permeability suggests that further optimization may be required for enhanced CNS bioavailability. While our findings are promising, they do have certain limitations. The chemical characterization of the extract's bioactive components remains tentative, and there is a lack of experimental validation regarding HIF‐1α protein expression and binding affinity assays. These validations are essential to confirm the mechanistic predictions derived from molecular docking. Despite these limitations, our results offer valuable insights into the phytochemical and biological potential and provide a strong basis for future studies focused on active component isolation and molecular mechanistic validation. The biodiversity of Algeria's edible plant species, especially those belonging to the Anacardiaceae family will also be valued with further research emphasizing the assessment of additional biological activities. Experimental Section Crude Extract Preparation The aerial parts of P. lentiscus were gathered in the Chlef region (36° 10’ 0.001″ N, 1° 19’ 59.999″ E), Algeria. The plant was authenticated by Professor Salima Benhouhou from the department of botany, Higher National Agronomic School (ENSA), Algiers, Algeria, where a voucher specimen (NO. 858) was deposited. The procedure outlined by Zhou et al. [91] was used to prepare the extract. After carefully weighing 70 g of P. lentiscus leaves, 20 g of anhydrous sodium sulfate was added to a Soxhlet thimble. A 500 mL round‐bottom flask was then filled with 300 mL of 80% methanol. In a water bath that was thermostatically controlled and stirred at 1000 rpm, the extraction was performed at 70°C. A Büchi rotary evaporator was then used to extract the solvent at a lower pressure. Pharmacological studies were conducted using the resultant extract. Phytochemical Analyses Total Phenolics Content In according to Singleton et al. [92], the Folin‐Ciocalteu reagent (Sigma‐Aldrich, St. Louis, MO, USA) was used to determine the total phenolic content (TPC) of P. lentiscus extract. The results were displayed as milligrams of gallic acid equivalents (GAE) per gram of extract. Total Flavonoids Content The total flavonoids content (TFC) of P. lentiscus extract was measured using the method outlined by Zhishen et al. [93]. The results were expressed in milligrams of quercetin equivalents (QE) per gram of extract. Phenolic Profiling by HPLC‐PDA ‐ESI‐MS A Thermo Finnigan Surveyor Plus HPLC apparatus with a quaternary pump, a Surveyor UV–vis photodiode array (PDA) detector, and an LCQ Advantage max ion trap mass spectrometer (Thermo Fisher Scientific, Waltham, MA) connected to an electrospray ionization (ESI) source was used to perform the chromatographic separation [94]. For the analysis, a Gemini C18 110 Å (150×2 mm, 5 µm) was utilized. An elution gradient containing a solution of water (solvent A) and MeOH (solvent B), both acidified with 0.1% formic acid, was used to separate the samples under the following conditions (time: % B): 20–25 min: 60%; 35 min: 90%; 40–55 min: 100%; 0–8 min: 45%; and 10–15 min: 55%. Analyses were carried out at 40°C and 1 mL/min of flow rate. The volume of injection was 5 µL. The chromatograms were recovered at 280 nm. A mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA) with an ESI interface is connected to the HPLC system. It uses a capillary voltage of 4500 V, a temperature of 350°C, a gas flow rate of 10 L/min, and a nebulizer pressure of 35 psi. It also considers a mass range of 100 to 1600 m/z. The contents of three compounds identified in this study were calculated by the external standard method, that is, by referring to the peak area of standard compounds [95]. In Vitro Antioxidant Activity 2,2′‐Diphenyl‐1‐picrylhydrazyl (DPPH) Activity The extract's antioxidant activity was examined in accordance with Blois's earlier findings [96]. Briefly, 1 mL of DPPH solution (0.1 mM) in methanol was mixed with three milliliters of sample solution in methanol at various concentrations. After half an hour, the absorbance at 517 nm was measured. The DPPH radical‐scavenging activity was calculated using the following formula: %Inhibition=A0−A1A0×100 where A0 was the absorbance of the control (without extract) and A1 was the absorbance in the presence of the extract. Ferric Reducing Antioxidant Power (FRAP) The procedure set out by Benzie and Strain [97] was followed in the ferric reducing antioxidant power test. 25mL of sodium acetate buffer (pH 3.6), 10 mL of 10 mM 2,4,6‐tripyridyl‐s‐triazine (TPTZ), and 10 mL of 20 mM FeCl3.6H2O were combined to prepare the FRAP reagent. The test involved mixing 10 µL of the extract, 65 µL of distilled water, and 2250 µL of the FRAP reagent. The extract solution was substituted with distilled water as a blank. At room temperature, the absorbance at 593 nm was measured after 8 min of incubation. Animals A total of 24 female Wistar albino rats weighing 180–200 g and 53 female NMRI albino mice weighing 22–25 g were used in the tests. The rodents were purchased from the Pasteur Institute of Algeria (IPA) (Algiers, Algeria). There were five animals in each cage, steel grating coverings, a feeding pit, and a steel separating bar for food during the 10‐day stay. The animals were kept at 25°C–27°C with regular temperature and humidity checks under a 12 h light/12 h dark light cycle. They were given a standard diet. Food and water were given ad libitum. The in vivo studies were carried out from 10:00 am to 4:00 pm. Authorizations and ethical rules were obtained in accordance with Executive Decree No. 10‐90, which supplements Executive Decree No. 04‐82 of the Algerian government, outlining the conditions and procedures for approving animal welfare in animal facilities. This work has been approved by the Ethics Committee of the Houari Boumediene University of Science and Technology and the Algerian Association for the Science of Experimental Animals (AASEA) (Agreement number 45/DGLPAG/DVA.SDA.14). Oral Acute Toxicity The crude extract of P. lentiscus leaves was tested for acute oral toxicity using the limit test standard of the OECD No. 425 Guideline. A female mouse was given 2 g/kg of the extract orally by gavage on the first day of the test after fasting for four hours. Abnormalities in skin, urination, lacrimation, decreased feeding activity, excitation, paw licking, increased respiration rate, decreased motor activity, diarrhea, weight loss, and paralysis were among the behavioral and physical changes that were closely observed during the course of a day. Particular attention was paid to the first four hours of the test. Considering the first mouse's findings, four additional female mice were recruited, fasted for four hours, and then administered a single dosage of the crude extract (2 g/kg) under the same careful observation. Two weeks were allocated to exploring for signs of toxicity. Pharmacological Studies Drugs and Treatments Random assignment was used to place six male NMRI mice in each group. The blank control group received a physiological solution (NaCl, 0.9%), while the positive control group received 400 mg/kg of piracetam (CAS 7491‐74‐9). The screening doses of P. lentiscus extract were 200 mg/kg and 400 mg/kg b.w./day. The treatments were administered once daily for seven days [98]. Normobaric Hypercapnic Hypoxia Test The normobaric hypercapnic hypoxia was reproduced in a 200 cm3 enclosed chamber. The mice were placed in a glass box that was tightly sealed and contained medical soda lime sixty minutes after the last treatment. The survival time during oxygen deprivation was recorded [7]. Sodium Nitrite Toxicosis Test In order to induce acute hemic hypoxia 60 min after the last treatment, sodium nitrite (240 mg/kg) was administered subcutaneously as a methemoglobin‐forming agent. The lifespan of the animals, estimated from the point of hypoxia induction was measured in minutes. The activity of the extract was assessed by comparing the lifespan of the test animals to that of the blank control group. Results were presented as a percentage (%) [10]. At the end of the experiment, the animals were promptly euthanized through cervical dislocation and decapitation. The brain was then extracted, weighed, and homogenized in cold Tris‐HCl buffer (pH 7.4). Biochemical assays were conducted immediately [7]. Open Field Test The effect of the extract on orientation (exploratory) and locomotor activity was evaluated using the open‐field test. The test was conducted under standard lighting and at the same time of day. The open‐field apparatus consisted of an open‐top box measuring 72 cm by 72 cm, with walls that were 36 cm high. White visible lines were drawn on the floor with a marker, dividing it into 16 squares of 18 cm by 18 cm each. A rat was placed in the center of the field, and its locomotor activity was observed for 3 min. The horizontal activity was quantified by counting the number of crossed sectors, while the vertical activity was measured by counting the instances of rearing. The emotional state was assessed by evaluating the anxiety level in the rats, which was determined by the number of grooming episodes [99]. Seventy percent ethyl alcohol was used to clean the box between tests. The behavior of the animals was continuously recorded using a video camera. Lipid Peroxidation Measurement The content of thiobarbituric acid reactive substances (TBARS) in the brain homogenate supernatants was determined using the method of Buege and Aust [100]. First, 1 mL of 17% trichloroacetic acid was added to 2.5 mL of the homogenate. The precipitate was separated by centrifugation for 10 min at 4000 g and 4°C. Then, 1 mL of a 0.8% aqueous solution of thiobarbituric acid was added to 2 mL of the supernatant. The samples were incubated in a boiling water bath until a pink color appeared, indicating the formation of the trimethine complex, and were subsequently cooled to room temperature. The absorbance was measured at 532 nm. The TBARS in the supernatant were estimated by spectrophotometry at 532 nm (ε532=1.56×105M−1cm−1) and the values expressed as nmol/mg of wet tissue [101]. Data Analysis IBM SPSS Statistics version 21 (IBM SPSS Statistics 21) was used to conduct statistical analysis. Data from biochemical and behavioral investigations were examined for differences between individual pairs of experimental groups using a one‐way ANOVA and post‐hoc Dunnett's test. When the p‐value was less than 0.05, it was deemed statistically significant (p < 0.05). Computational Details PASS Analysis The molecular structures of the phytocomponents identified in P. lentiscus were retrieved from the PubChem database (http://pubchem.ncbi.nlm.nih.gov/) in MOL file format. To computationally screen these eight compounds for their potential biological activities, we utilized the Prediction of Activity Spectra for Substances (PASS, available in http://www.pharmaexpert.ru/PASSonline/predict.php) online tool. The PASS prediction algorithm is based on Multilevel Neighborhoods of Atoms (MNA) descriptors, which are 2D structural fragments that establish a compound's biological activity as a function of its molecular structure. The PASS algorithm predicts potential biological activities by providing two probability scores for each activity: Pa (probability of being active) and Pi (probability of being inactive). A compound is considered likely to exhibit a particular biological effect if its Pa value exceeds its Pi value for that activity [6]. Molecular Docking Analysis This section describes the computational interpretation of the biological effects exhibited by P. lentiscus compounds (gallic acid, catechin, and luteolin) against the target protein, human hypoxia‐inducible factor 1α (HIF‐1α). For this analysis, the crystal structure of HIF‐1α (PDB ID: 1H2K) was downloaded from the RCSB Protein Data Bank (PDB) (https://www.rcsb.org/). In the molecular docking procedure, 7‐hydroxylamellarin A was employed as a reference molecule for comparative study [82]. Protein preparation was performed using UCSF Chimera V 1.19, involving the optimization of all possible conformations and protonated forms of the selected protein. For the ligands, we obtained the PubChem IDs, molecular weights, and 3D structures of the ligands in SDF format from the PubChem database. These structures were then opened in UCSF Chimera V 1.19 and their energy was minimized using the Gasteiger mode. Finally, the ligands were prepared for docking by adding hydrogen atoms, setting charges to zero, and saving them in PDB format. Following the preparation of the protein and ligands data, the AutoDock Vina software [102] was utilized to calculate the binding affinities (kcal.mol−1) between the protein and the ligand molecules using the Lamarckian genetic algorithm methodology. Upon completion of docking, the resulting interactions between HIF‐1α and the ligands were visualized using Discovery Studio Visualizer (BIOVIA, D.S.), Drug Metabolism and Pharmacokinetics Analysis A small molecule's pharmacokinetic destiny includes its absorption, distribution, metabolism, and excretion (ADME), which is determined by a precisely regulated series of physiological and biochemical processes that control membrane penetration, systemic circulation, enzymatic conversion, and ultimate clearance. Anticipating drug efficacy and safety requires precise delineation of these phases, and contemporary in silico platforms now allow for quick, structure‐based prediction of the crucial parameters involved [103]. Two complimentary web servers, SwissADME and pkCSM were used to study the ADMET profiles of the investigated P. lentiscus components and piracetam. The molecular structures were imported as canonical SMILES from the PubChem database. SwissADME offers a thorough examination of a compound's pharmacokinetic characteristics, including physicochemical and drug‐likeness property predictions. Graph‐based predictions of human intestinal absorption, cytochrome‐mediated metabolism, renal excretion, and toxicity parameters were generated by pkCSM [103]. Author Contribution Halima Saiah: Supervision, investigation, conceptualization, original draft writing. Ali Zineddine Boumehira and Wassila Saiah: Molecular docking analyses, admet profiling and data interpretation. Halima Saiah and Salima Boudane: Formal in vitro and in vivo analysis. Asma Al‐farajein: Investigation, original draft writing, and figures preparation. All authors reviewed and approved the final manuscript. Funding The authors have nothing to report. Conflicts of Interest The authors declare no conflicts of interest. Supporting information This material provides a detailed chromatographic profile of the extract from P. lentiscus (Figure S1). It also includes the biological properties of the identified compounds, calculated using the PASS online platform (Table S1), as well as the ADMET profile for gallic acid, catechin, luteolin, and the reference drug piracetam (Table S2). Supporting File 1: cbdv71733‐sup‐0001‐SuppMat.docx